The effect of supplementation of omega-3 and zinc on the treatment of type 2 diabetes

Evaluating the effect of omega-3 and zinc oral supplementation on glycemic index, serum zinc levels, body composition and blood pressure in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170214032571N9

Enrollment

Registered

2018-01-30

Start date

2016-09-30

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus

Interventions

Intervention 1: Intervention group: Group A = Intervention with omega-3 at a dose of 1000 mg daily one number capsule for 8 weeks - Dana Pharmaceutical Company. Intervention 2: Intervention group: In

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age range over 18 years old in both sexes Type 2 diabetes

Exclusion criteria

Exclusion criteria: Insulin injection Pregnancy and lactation Pancreatic cancer Severe physical activity during the intervention

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: At weeks 0, 8. Method of measurement: Scale, Kg.;Body mass index. Timepoint: At weeks 0, 8. Method of measurement: Weight(kg) / Height(m)².;Insulin resistance. Timepoint: At weeks 0, 8. Method of measurement: (fasting serum glucose (mmol/L) × fasting serum insulin (µIU/ml))/22.5.;Fasting Blood Sugar. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.;Quantitative Insulin Sensitivity Check Index. Timepoint: At weeks 0, 8. Method of measurement: 1/ [ log(fasting insulin, µU/ml) + log (fasting glucose, mg/dl) ].;Serum insulin. Timepoint: At weeks 0, 8. Method of measurement: Radioimmunoassay.;Serum zinc. Timepoint: At weeks 0, 8. Method of measurement: Colorimetric.;Systolic blood pressure. Timepoint: At weeks 0, 8. Method of measurement: Mercury pressure gauge, Mm mercury.;Diastolic blood pressure. Timepoint: At weeks 0, 8. Method of measurement: Mercury pressure gauge, Mm mercury.	—

Measure

Time frame

Weight. Timepoint: At weeks 0, 8. Method of measurement: Scale, Kg.;Body mass index. Timepoint: At weeks 0, 8. Method of measurement: Weight(kg) / Height(m)².;Insulin resistance. Timepoint: At weeks 0, 8. Method of measurement: (fasting serum glucose (mmol/L) × fasting serum insulin (µIU/ml))/22.5.;Fasting Blood Sugar. Timepoint: At weeks 0, 8. Method of measurement: Enzymatic method, mg/dl.;Quantitative Insulin Sensitivity Check Index. Timepoint: At weeks 0, 8. Method of measurement: 1/ [ log(fasting insulin, µU/ml) + log (fasting glucose, mg/dl) ].;Serum insulin. Timepoint: At weeks 0, 8. Method of measurement: Radioimmunoassay.;Serum zinc. Timepoint: At weeks 0, 8. Method of measurement: Colorimetric.;Systolic blood pressure. Timepoint: At weeks 0, 8. Method of measurement: Mercury pressure gauge, Mm mercury.;Diastolic blood pressure. Timepoint: At weeks 0, 8. Method of measurement: Mercury pressure gauge, Mm mercury.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Monafi

Oroumia University of Medical Sciences

majidmanafi@yahoo.com+98 44 1278 0803

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026